The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Advice for community physicians managing and treating patients with WM
Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, discusses recommendations for community physicians treating patients with Waldenström’s macroglobulinemia (WM), emphasizing the importance of correct diagnosis. Dr Castillo explains that asymptomatic patients should not be treated due to the potential toxicity of therapies, with chemoimmunotherapy and BTK inhibitors (BTKis) being the primary options for those who need treatment. He also highlights the importance of considering clinical trials for all patients with WM. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
